The Filings Report

Edwards Lifesciences Corp

EWNYSECIK 1099800Healthcare / Medical Devicesfiscal year ends December70 quarters since 2009

Revenue, Q2 FY2026
$1.7B
+13.6% on Q2 FY2025
Net income
$242M
−27.4% on Q2 FY2025
Free cash flow
$585M
+142.8% on Q2 FY2025
Diluted EPS
$0.42
−25.0% on Q2 FY2025
Revenue, TTM
$6.5B
trailing four quarters
Net margin, TTM
15.4%
net income $1.0B
Free cash flow, TTM
$1.4B
$1.7B less $287M capex
Cash and equivalents
$2.9B
long-term debt $599M, Jun 30, 2026
Shares, 12-month change
−1.8%
576M shares, Jun 30, 2026
Buybacks, TTM
$1.2B
2.3% of market value
Dividends, TTM
—
no yield
Market value
$53.0B
at the close, buybacks

Latest quarter Q2 FY2026, filed August 4, 2026. Trailing figures sum the latest four quarters. Market values at the latest close, from a market data vendor.

In Q2 FY2026, the quarter ended June 30, 2026, Edwards Lifesciences Corp reported revenue of $1.7B, +13.6% on Q2 FY2025, and net income of $242M (−27.4%). Operating margin was 29.5%. Free cash flow, operating cash flow less capital expenditures, was $585M ($652M less $67M). Diluted earnings per share were $0.42.

The last 16 quarters

Q3 FY2022 to Q2 FY2026, through the filing of August 4, 2026.

Revenue and net incomeRevenueNet income
$0$1B$2B$3B$4BQ3'22, Revenue: $1.3BQ3'22, Net income: $344MQ3'22Q4'22, Revenue: $430MQ4'22, Net income: $398MQ4'22Q1'23, Revenue: $1.2BQ1'23, Net income: $341MQ1'23Q2'23, Revenue: $1.3BQ2'23, Net income: $307MQ2'23Q3'23, Revenue: $1.2BQ3'23, Net income: $385MQ3'23Q4'23, Revenue: $1.3BQ4'23, Net income: $370MQ4'23Q1'24, Revenue: $1.3BQ1'24, Net income: $352MQ1'24Q2'24, Revenue: $1.4BQ2'24, Net income: $366MQ2'24Q3'24, Revenue: $1.4BQ3'24, Net income: $3.1BQ3'24Q4'24, Revenue: $1.4BQ4'24, Net income: $386MQ4'24Q1'25, Revenue: $1.4BQ1'25, Net income: $358MQ1'25Q2'25, Revenue: $1.5BQ2'25, Net income: $333MQ2'25Q3'25, Revenue: $1.6BQ3'25, Net income: $291MQ3'25Q4'25, Revenue: $1.6BQ4'25, Net income: $91MQ4'25Q1'26, Revenue: $1.6BQ1'26, Net income: $381MQ1'26Q2'26, Revenue: $1.7BQ2'26, Net income: $242MQ2'26$0$1B$2B$3B$4BQ3'22, Revenue: $1.3BQ3'22, Net income: $344MQ4'22, Revenue: $430MQ4'22, Net income: $398MQ4'22Q1'23, Revenue: $1.2BQ1'23, Net income: $341MQ2'23, Revenue: $1.3BQ2'23, Net income: $307MQ2'23Q3'23, Revenue: $1.2BQ3'23, Net income: $385MQ4'23, Revenue: $1.3BQ4'23, Net income: $370MQ4'23Q1'24, Revenue: $1.3BQ1'24, Net income: $352MQ2'24, Revenue: $1.4BQ2'24, Net income: $366MQ2'24Q3'24, Revenue: $1.4BQ3'24, Net income: $3.1BQ4'24, Revenue: $1.4BQ4'24, Net income: $386MQ4'24Q1'25, Revenue: $1.4BQ1'25, Net income: $358MQ2'25, Revenue: $1.5BQ2'25, Net income: $333MQ2'25Q3'25, Revenue: $1.6BQ3'25, Net income: $291MQ4'25, Revenue: $1.6BQ4'25, Net income: $91MQ4'25Q1'26, Revenue: $1.6BQ1'26, Net income: $381MQ2'26, Revenue: $1.7BQ2'26, Net income: $242MQ2'26

Net income losses drawn in red.

Free cash flow
−$200M$0$200M$400M$600MQ3'22, Free cash flow: $250MQ3'22Q4'22, Free cash flow: $214MQ4'22Q1'23, Free cash flow: $253MQ1'23Q2'23, Free cash flow: −$14MQ2'23Q3'23, Free cash flow: $356MQ3'23Q4'23, Free cash flow: $48MQ4'23Q1'24, Free cash flow: −$119MQ1'24Q2'24, Free cash flow: $286MQ2'24Q3'24, Free cash flow: $300MQ3'24Q4'24, Free cash flow: −$177MQ4'24Q1'25, Free cash flow: $224MQ1'25Q2'25, Free cash flow: $241MQ2'25Q3'25, Free cash flow: $516MQ3'25Q4'25, Free cash flow: $354MQ4'25Q1'26, Free cash flow: −$21MQ1'26Q2'26, Free cash flow: $585MQ2'26−$200M$0$200M$400M$600MQ3'22, Free cash flow: $250MQ4'22, Free cash flow: $214MQ4'22Q1'23, Free cash flow: $253MQ2'23, Free cash flow: −$14MQ2'23Q3'23, Free cash flow: $356MQ4'23, Free cash flow: $48MQ4'23Q1'24, Free cash flow: −$119MQ2'24, Free cash flow: $286MQ2'24Q3'24, Free cash flow: $300MQ4'24, Free cash flow: −$177MQ4'24Q1'25, Free cash flow: $224MQ2'25, Free cash flow: $241MQ2'25Q3'25, Free cash flow: $516MQ4'25, Free cash flow: $354MQ4'25Q1'26, Free cash flow: −$21MQ2'26, Free cash flow: $585MQ2'26

Operating cash flow less capital expenditures; negative quarters in red.

Cash and equivalents against long-term debtCash and equivalentsLong-term debt
$0$1B$2B$3B$4BQ3'22, Cash and equivalents: $1.2BQ3'22, Long-term debt: $596MQ3'22Q4'22, Cash and equivalents: $769MQ4'22, Long-term debt: $596MQ4'22Q1'23, Cash and equivalents: $873MQ1'23, Long-term debt: $597MQ1'23Q2'23, Cash and equivalents: $1.0BQ2'23, Long-term debt: $597MQ2'23Q3'23, Cash and equivalents: $1.4BQ3'23, Long-term debt: $597MQ3'23Q4'23, Cash and equivalents: $1.1BQ4'23, Long-term debt: $597MQ4'23Q1'24, Cash and equivalents: $1.2BQ1'24, Long-term debt: $597MQ1'24Q2'24, Cash and equivalents: $1.6BQ2'24, Long-term debt: $597MQ2'24Q3'24, Cash and equivalents: $3.7BQ3'24, Long-term debt: $598MQ3'24Q4'24, Cash and equivalents: $3.0BQ4'24, Long-term debt: $598MQ4'24Q1'25, Cash and equivalents: $3.1BQ1'25, Long-term debt: $598MQ1'25Q2'25, Cash and equivalents: $3.3BQ2'25, Long-term debt: $598MQ2'25Q3'25, Cash and equivalents: $2.7BQ3'25, Long-term debt: $598MQ3'25Q4'25, Cash and equivalents: $2.9BQ4'25, Long-term debt: $598MQ4'25Q1'26, Cash and equivalents: $2.4BQ1'26, Long-term debt: $599MQ1'26Q2'26, Cash and equivalents: $2.9BQ2'26, Long-term debt: $599MQ2'26$0$1B$2B$3B$4BQ3'22, Cash and equivalents: $1.2BQ3'22, Long-term debt: $596MQ4'22, Cash and equivalents: $769MQ4'22, Long-term debt: $596MQ4'22Q1'23, Cash and equivalents: $873MQ1'23, Long-term debt: $597MQ2'23, Cash and equivalents: $1.0BQ2'23, Long-term debt: $597MQ2'23Q3'23, Cash and equivalents: $1.4BQ3'23, Long-term debt: $597MQ4'23, Cash and equivalents: $1.1BQ4'23, Long-term debt: $597MQ4'23Q1'24, Cash and equivalents: $1.2BQ1'24, Long-term debt: $597MQ2'24, Cash and equivalents: $1.6BQ2'24, Long-term debt: $597MQ2'24Q3'24, Cash and equivalents: $3.7BQ3'24, Long-term debt: $598MQ4'24, Cash and equivalents: $3.0BQ4'24, Long-term debt: $598MQ4'24Q1'25, Cash and equivalents: $3.1BQ1'25, Long-term debt: $598MQ2'25, Cash and equivalents: $3.3BQ2'25, Long-term debt: $598MQ2'25Q3'25, Cash and equivalents: $2.7BQ3'25, Long-term debt: $598MQ4'25, Cash and equivalents: $2.9BQ4'25, Long-term debt: $598MQ4'25Q1'26, Cash and equivalents: $2.4BQ1'26, Long-term debt: $599MQ2'26, Cash and equivalents: $2.9BQ2'26, Long-term debt: $599MQ2'26

Positions at each quarter end, as filed; short-term investments are not included.

Income statement

Last eight quarters, newest first, through Q2 FY2026 filed August 4, 2026.

Edwards Lifesciences Corp income statement, quarterly
Millions of dollarsQ2 FY2026ended Jun 30, 2026filed Aug 4, 2026Q1 FY2026ended Mar 31, 2026filed May 6, 2026Q4 FY2025ended Dec 31, 2025filed Feb 25, 2026Q3 FY2025ended Sep 30, 2025filed Nov 5, 2025Q2 FY2025ended Jun 30, 2025filed Aug 6, 2025Q1 FY2025ended Mar 31, 2025filed May 6, 2025Q4 FY2024ended Dec 31, 2024filed Feb 28, 2025Q3 FY2024ended Sep 30, 2024filed Nov 6, 2024YoYQ2 FY2026vs Q2 FY2025
Revenue1,7411,6491,5701,5531,5321,4131,3861,354+13.6%
Cost of revenue392363343345344302292263+13.9%
Gross profit1,3491,2861,2271,2081,1881,1111,0941,092+13.5%
Research and development279263268281276255271253+1.0%
Selling, general and administrative561522603515502466492421+11.8%
Operating income513478151307411395313351+24.8%
Other income (expense)7(19)(61)41(11)397852+160.0%
Pretax income52045990348400434390403+29.9%
Income tax27878265664704541+333.0%
Net income242381912913333583863,071−27.4%
Diluted EPS ($)0.420.66—0.500.560.610.655.13−25.0%
Diluted shares (millions)578581—586588588—598—

Fourth quarters are the fiscal year less the first nine months when the filer reports no discrete fourth quarter, and are marked. Diluted EPS is never derived, so a derived quarter shows none. Italic figures are derived.

Balance sheet

Last eight quarters, newest first, through Q2 FY2026 filed August 4, 2026.

Edwards Lifesciences Corp balance sheet, quarterly
Millions of dollarsQ2 FY2026ended Jun 30, 2026filed Aug 4, 2026Q1 FY2026ended Mar 31, 2026filed May 6, 2026Q4 FY2025ended Dec 31, 2025filed Feb 25, 2026Q3 FY2025ended Sep 30, 2025filed Nov 5, 2025Q2 FY2025ended Jun 30, 2025filed Aug 6, 2025Q1 FY2025ended Mar 31, 2025filed May 6, 2025Q4 FY2024ended Dec 31, 2024filed Feb 28, 2025Q3 FY2024ended Sep 30, 2024filed Nov 6, 2024YoYQ2 FY2026vs Q2 FY2025
Cash and equivalents2,9072,4462,9382,6863,2733,1413,0453,676−11.2%
Short-term investments1,3461,2261,2881,156789758931770+70.5%
Total current assets6,8196,2296,7396,3596,5776,2136,2856,728+3.7%
Total assets13,86713,32113,69713,27213,48913,02213,05512,971+2.8%
Total current liabilities1,5081,4091,8141,5881,4051,3951,5051,944+7.3%
Long-term debt599599598598598598598598+0.1%
Total liabilities3,1422,9943,3603,0672,8822,8312,9923,360+9.0%
Stockholders’ equity10,61810,32810,33810,20510,54510,1299,9989,546+0.7%
Shares outstanding (millions)576576581580587587588590—

Positions at each period end. Nothing on this statement is derived. Long-term debt is the filed noncurrent line only; no total-debt composite is constructed across filers. Italic figures are derived.

Cash flow statement

Last eight quarters, newest first, through Q2 FY2026 filed August 4, 2026.

Edwards Lifesciences Corp cash flow statement, quarterly
Millions of dollarsQ2 FY2026ended Jun 30, 2026filed Aug 4, 2026Q1 FY2026ended Mar 31, 2026filed May 6, 2026Q4 FY2025ended Dec 31, 2025filed Feb 25, 2026Q3 FY2025ended Sep 30, 2025filed Nov 5, 2025Q2 FY2025ended Jun 30, 2025filed Aug 6, 2025Q1 FY2025ended Mar 31, 2025filed May 6, 2025Q4 FY2024ended Dec 31, 2024filed Feb 28, 2025Q3 FY2024ended Sep 30, 2024filed Nov 6, 2024YoYQ2 FY2026vs Q2 FY2025
Operating cash flow65244451574290280(127)352+124.6%
Capital expenditures6765975849565052+35.7%
Free cash flow (CFO − capex)585(21)354516241224(177)300+142.8%
Depreciation and amortization4341433938374335+12.1%
Share repurchases153422415896259100901+2687.3%
Dividends paid—————————

10-Qs file cash flows as year-to-date totals, so quarterly figures are differenced from consecutive filings and marked. Free cash flow is operating cash flow less capital expenditures, computed from the two filed lines. Italic figures are derived.

Annual statements

Every fiscal year filed, newest first, through FY2025 filed February 25, 2026.

Income statement

Edwards Lifesciences Corp income statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 25, 2026FY2024ended Dec 31, 2024filed Feb 28, 2025FY2023ended Dec 31, 2023filed Feb 12, 2024FY2022ended Dec 31, 2022filed Feb 13, 2023FY2021ended Dec 31, 2021filed Feb 14, 2022FY2020ended Dec 31, 2020filed Feb 12, 2021FY2019ended Dec 31, 2019filed Feb 14, 2020FY2018ended Dec 31, 2018filed Feb 15, 2019FY2017ended Dec 31, 2017filed Feb 16, 2018FY2016ended Dec 31, 2016filed Feb 17, 2017FY2015ended Dec 31, 2015filed Feb 19, 2016FY2014ended Dec 31, 2014filed Feb 20, 2015FY2013ended Dec 31, 2013filed Feb 28, 2014FY2012ended Dec 31, 2012filed Feb 28, 2013FY2011ended Dec 31, 2011filed Feb 27, 2012FY2010ended Dec 31, 2010filed Feb 28, 2011FY2009ended Dec 31, 2009filed Aug 6, 2010FY2008ended Dec 31, 2008filed Aug 6, 2010
Revenue6,0685,4405,0104,4645,2334,3864,3483,7233,4352,9642,4942,3232,0461,9001,6791,4471,3211,238
Cost of revenue1,3341,1189787241,2491,0811,114939875797617626517491490408399420
Gross profit4,7334,3224,0323,7403,9843,3063,2342,7832,5602,1661,8771,6971,5291,4091,1891,039922818
Research and development1,0791,053963844903761753622553442383347323291246204176139
Selling, general and administrative2,0851,7891,5831,3581,4941,2281,2421,089991905851858733697642550509481
Operating income1,2641,3791,3091,4981,6908981,1477481,089751————————
Other income (expense)91696421131284(1)(5)(4)(8)——584(8)
Pretax income1,2731,5481,3721,5201,7029171,1677611,0357386221,144511388284268304164
Income tax21715215219619993120394511681283331229747507536
Net income1,0744,1751,4021,5221,5038231,047722584570495811389292237218229—
Diluted EPS ($)1.836.972.302.442.381.301.641.130.90*0.87*0.75*1.25*0.57*0.41*0.33*0.30*0.33*0.18*
Diluted shares (millions)586599609624631632637641648*653*661*651*683*710*716*715*705*715*

Balance sheet

Edwards Lifesciences Corp balance sheet, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 25, 2026FY2024ended Dec 31, 2024filed Feb 28, 2025FY2023ended Dec 31, 2023filed Feb 12, 2024FY2022ended Dec 31, 2022filed Feb 13, 2023FY2021ended Dec 31, 2021filed Feb 14, 2022FY2020ended Dec 31, 2020filed Feb 12, 2021FY2019ended Dec 31, 2019filed Feb 14, 2020FY2018ended Dec 31, 2018filed Feb 15, 2019FY2017ended Dec 31, 2017filed Feb 16, 2018FY2016ended Dec 31, 2016filed Feb 17, 2017FY2015ended Dec 31, 2015filed Feb 19, 2016FY2014ended Dec 31, 2014filed Feb 20, 2015FY2013ended Dec 31, 2013filed Feb 28, 2014FY2012ended Dec 31, 2012filed Feb 28, 2013FY2011ended Dec 31, 2011filed Feb 27, 2012FY2010ended Dec 31, 2010filed Feb 28, 2011FY2009ended Dec 31, 2009filed Aug 6, 2010FY2008ended Dec 31, 2008filed Aug 6, 2010
Cash and equivalents2,9383,0451,1327698631,1831,179714818930718654420311171396334219
Short-term investments1,288931501446604219338242519341506785517—————
Total current assets6,7396,2854,0363,0963,1813,0912,9842,2872,5492,2402,0482,2311,7261,2921,1691,033889—
Total assets13,69713,0559,3638,2938,5037,2376,4885,3245,6664,5104,0563,5232,7102,2221,9811,7671,616—
Total current liabilities1,8141,5051,1951,0221,0328949028771,420533476426346347335338291—
Long-term debt598598597596596595594594438822597598593189——90—
Total liabilities3,3602,9922,6442,4862,6672,663————————————
Stockholders’ equity10,3389,9986,6505,8075,8364,5744,1483,1402,9562,6192,5032,1911,5441,4671,3271,3081,158879
Shares outstanding (millions)581588601608623625627*623*630*637*644*647*643*685*690*689*——

Cash flow statement

Edwards Lifesciences Corp cash flow statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 25, 2026FY2024ended Dec 31, 2024filed Feb 28, 2025FY2023ended Dec 31, 2023filed Feb 12, 2024FY2022ended Dec 31, 2022filed Feb 13, 2023FY2021ended Dec 31, 2021filed Feb 14, 2022FY2020ended Dec 31, 2020filed Feb 12, 2021FY2019ended Dec 31, 2019filed Feb 14, 2020FY2018ended Dec 31, 2018filed Feb 15, 2019FY2017ended Dec 31, 2017filed Feb 16, 2018FY2016ended Dec 31, 2016filed Feb 17, 2017FY2015ended Dec 31, 2015filed Feb 19, 2016FY2014ended Dec 31, 2014filed Feb 20, 2015FY2013ended Dec 31, 2013filed Feb 28, 2014FY2012ended Dec 31, 2012filed Feb 28, 2013FY2011ended Dec 31, 2011filed Feb 27, 2012FY2010ended Dec 31, 2010filed Feb 28, 2011FY2009ended Dec 31, 2009filed Aug 6, 2010FY2008ended Dec 31, 2008filed Aug 6, 2010
Operating cash flow1,5955428961,2181,7321,0541,1839271,001704550————251165153
Capital expenditures2602522532453264072542391681761038310910977626451
Free cash flow (CFO − capex)1,3352906439741,406647929688833528447————190101103
Depreciation and amortization157155145140135107897782716669635458575956
Share repurchases8931,1598801,72751362526379676366228030149734430320096307
Dividends paid——————————————————

Insider activity

Form 4 filings by officers, directors and 10% owners, November 1, 2024 to November 1, 2026. Only open-market purchases and sales count as buys and sells; awards, exercises, tax withholding and gifts are listed in grey and never counted.

Bought, three months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, three months
$3M
8 sales by 5 insiders; officers and directors $3M
Bought, twelve months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, twelve months
$28M
54 sales by 9 insiders; officers and directors $28M

The last 25 transactions

TradedInsiderRoleTransactionSharesPriceValueHeld afterFiled
Oct 8, 2026Lippis Daniel J.CVP, TAVRoption exercise619$72.68$45K40,653Oct 8, 2026
Oct 8, 2026Lippis Daniel J.CVP, TAVRopen-market sale10b5-1619$85.65$53K40,034Oct 8, 2026
Sep 14, 2026Markowitz WayneCVP, JAPACtax withholding568$84.37$48K19,371Sep 14, 2026
Sep 13, 2026Dahl Andrew M.SVP, Corporate Controllertax withholding253$84.37$21K14,615Sep 14, 2026
Sep 11, 2026Markowitz WayneCVP, JAPACtax withholding355$86.77$31K19,939Sep 14, 2026
Sep 11, 2026Chopra DaveenCVP, TMTT, Surgical & IHFMtax withholding398$86.77$35K43,926Sep 11, 2026
Sep 11, 2026Lippis Daniel J.CVP, TAVRoption exercise619$72.68$45K40,653Sep 11, 2026
Sep 11, 2026Lippis Daniel J.CVP, TAVRopen-market sale10b5-1619$87.51$54K40,034Sep 11, 2026
Aug 31, 2026Dahl Andrew M.SVP, Corporate Controlleropen-market sale544$91.06$50K14,868Aug 31, 2026
Aug 28, 2026Bruls AnnetteCVP, EMEACLAopen-market sale2,644$89.98$238K17,984Aug 28, 2026
Aug 26, 2026Chopra DaveenCVP, TMTT, Surgical & IHFMoption exercise31,800$72.68$2M76,124Aug 26, 2026
Aug 26, 2026Chopra DaveenCVP, TMTT, Surgical & IHFMopen-market sale1,154$91.76$106K74,970Aug 26, 2026
Aug 26, 2026Chopra DaveenCVP, TMTT, Surgical & IHFMopen-market sale30,646$90.99$3M44,324Aug 26, 2026
Aug 26, 2026Markowitz WayneCVP, JAPACopen-market sale1,240$91.47$113K20,294Aug 26, 2026
Aug 11, 2026Lippis Daniel J.CVP, TAVRoption exercise619$72.68$45K40,653Aug 11, 2026
Aug 11, 2026Lippis Daniel J.CVP, TAVRopen-market sale10b5-1619$92.03$57K40,034Aug 11, 2026
Jul 30, 2026Markowitz WayneCVP, JAPACopen-market sale146$86.03$13K21,534Jul 30, 2026
Jul 28, 2026Markowitz WayneCVP, JAPACoption exercise9,628$74.02$713K31,308Jul 28, 2026
Jul 28, 2026Markowitz WayneCVP, JAPACopen-market sale9,628$85.06$819K21,680Jul 28, 2026
Jul 27, 2026Zovighian Bernard JCEO, Directorgift320$0.00—98,845Jul 27, 2026
Jul 27, 2026Zovighian Bernard JCEO, Directorgiftindirect320$0.00—11,836Jul 27, 2026
Jul 27, 2026Zovighian Bernard JCEO, Directoropen-market saleindirect2,921$83.93$245K8,916Jul 27, 2026
Jul 11, 2026Bruls AnnetteCVP, EMEACLAtax withholding109$92.21$10K20,628Jul 13, 2026
Jul 10, 2026Lippis Daniel J.CVP, TAVRoption exercise619$72.68$45K40,653Jul 10, 2026
Jul 10, 2026Lippis Daniel J.CVP, TAVRopen-market sale10b5-1619$91.70$57K40,034Jul 10, 2026

Full insider history for Edwards Lifesciences Corp, or insider activity across all companies. A record of filings, not a recommendation.

Tracked funds holding it

1 of the tracked managers held EW in their latest 13F filing, through August 14, 2026. Weight is the share of the fund’s reported portfolio. How the funds have traded EW by quarter.

FundManagerQuarterValueSharesWeightMove
Baron Capital GroupRon BaronQ2 2026$21M229,6030.03%added +457.6%

Sources

Fiscal year ends in month 12; periods are labeled with the issuer's own fiscal calendar. Values are as most recently filed (restatements apply; per-share values are on current split basis per the connector's split table, flagged in adjusted). Flow items flagged in `derived` were computed (Q4 = FY − nine months; quarterly cash flow differenced from year-to-date filings) rather than read from a filing. `reconciliation.repaired` lists periods where a full-year figure was filed in a quarter slot: that row was dropped and the quarter rebuilt from the annual figure. `reconciliation.quarantined` lists periods where four filed quarters do not sum to the filed year — those quarterly values are withheld, so a blank there is a withholding rather than an absence of reporting.

Filer
Edwards Lifesciences Corporation, CIK 1099800 on EDGAR
Extract generated
October 6, 2026
Withheld
5 line-years whose four quarters do not sum to the filed year: cost of revenue FY2023, operating income FY2023, opex sga FY2023, pretax income FY2023, rnd FY2023
Repaired
1 quarters where a full-year figure was filed in a quarter slot and the quarter was rebuilt: other income FY2017
XBRL concepts behind each line

Income statement

Revenue: RevenueFromContractWithCustomerExcludingAssessedTax, SalesRevenueNet
Cost of revenue: CostOfGoodsAndServicesSold
Gross profit: GrossProfit
Research and development: ResearchAndDevelopmentExpense
Selling, general and administrative: SellingGeneralAndAdministrativeExpense
Operating income: OperatingIncomeLoss
Other income (expense): NonoperatingIncomeExpense, OtherNonoperatingIncomeExpense
Pretax income: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest, IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
Income tax: IncomeTaxExpenseBenefit
Net income: NetIncomeLoss, NetIncomeLossAvailableToCommonStockholdersBasic
Diluted EPS ($): EarningsPerShareDiluted
Diluted shares (millions): WeightedAverageNumberOfDilutedSharesOutstanding

Balance sheet

Cash and equivalents: CashAndCashEquivalentsAtCarryingValue
Short-term investments: ShortTermInvestments
Total current assets: AssetsCurrent
Total assets: Assets
Total current liabilities: LiabilitiesCurrent
Long-term debt: LongTermDebtNoncurrent
Total liabilities: Liabilities
Stockholders’ equity: StockholdersEquity
Shares outstanding (millions): dei:EntityCommonStockSharesOutstanding

Cash flow statement

Operating cash flow: NetCashProvidedByUsedInOperatingActivities
Capital expenditures: PaymentsToAcquirePropertyPlantAndEquipment
Free cash flow (CFO − capex): not filed
Depreciation and amortization: DepreciationDepletionAndAmortization
Share repurchases: PaymentsForRepurchaseOfCommonStock
Dividends paid: not filed

The data

The statements on this page as files, generated October 6, 2026.

JSON file
/data/financials/EW.json